Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Scientists say research into a vaccine for HIV is further along than it’s ever been.But Trump administration cuts to ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the ...

The immune system remains seriously out-of-whack—in an inflammatory state of overactivation and impaired ...

There is a need to address wrong theological teachings that prescribe only to miracle cure of HIV/Aids and denigrate science as being satanic. Four decades since the scientific discovery of the HIV ...

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

Once the virus attaches to receptor clusters, it sends signals that make the cell wrap it in a clathrin coat and build an actin bulge, pulling the virus inward. The virus is then pinched off into a ...

A 60-year-old man based in Berlin, Germany, has become the seventh known person in the world to achieve long-term HIV remission, thanks to undergoing cancer treatment for his leukemia. The patient had ...

A man has become the seventh person to be left HIV-free after receiving a stem cell transplant to treat blood cancer. Significantly, he is also the second of the seven who received stem cells that ...

On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, researchers have now identified a perineural pathway through which the HIV virus ...